GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (FRA:S49) » Definitions » Cyclically Adjusted PB Ratio

Supernus Pharmaceuticals (FRA:S49) Cyclically Adjusted PB Ratio : 2.70 (As of May. 22, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Supernus Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-22), Supernus Pharmaceuticals's current share price is €26.20. Supernus Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €9.72. Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 2.70.

The historical rank and industry rank for Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:S49' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.42   Med: 5.02   Max: 24.68
Current: 2.69

During the past years, Supernus Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 24.68. The lowest was 2.42. And the median was 5.02.

FRA:S49's Cyclically Adjusted PB Ratio is ranked worse than
62.26% of 681 companies
in the Drug Manufacturers industry
Industry Median: 1.88 vs FRA:S49: 2.69

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Supernus Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was €15.552. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €9.72 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Supernus Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supernus Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Supernus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.52 7.32 4.55 4.31 2.86

Supernus Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.12 3.25 2.83 2.86 3.19

Competitive Comparison of Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Supernus Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=26.20/9.72
=2.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supernus Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Supernus Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=15.552/131.7762*131.7762
=15.552

Current CPI (Mar. 2024) = 131.7762.

Supernus Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.583 100.560 0.764
201409 1.195 100.428 1.568
201412 0.768 99.070 1.022
201503 1.839 99.621 2.433
201506 1.883 100.684 2.464
201509 2.003 100.392 2.629
201512 1.649 99.792 2.178
201603 2.328 100.470 3.053
201606 2.535 101.688 3.285
201609 3.118 101.861 4.034
201612 3.638 101.863 4.706
201703 3.836 102.862 4.914
201706 4.024 103.349 5.131
201709 4.119 104.136 5.212
201712 4.405 104.011 5.581
201803 5.527 105.290 6.917
201806 6.406 106.317 7.940
201809 6.920 106.507 8.562
201812 7.611 105.998 9.462
201903 8.111 107.251 9.966
201906 8.823 108.070 10.758
201909 9.645 108.329 11.733
201912 10.201 108.420 12.399
202003 10.566 108.902 12.785
202006 11.238 108.767 13.615
202009 11.427 109.815 13.712
202012 11.581 109.897 13.887
202103 11.959 111.754 14.102
202106 12.269 114.631 14.104
202109 12.954 115.734 14.750
202112 13.558 117.630 15.189
202203 14.090 121.301 15.307
202206 14.881 125.017 15.686
202209 15.935 125.227 16.768
202212 15.420 125.222 16.227
202303 15.641 127.348 16.185
202306 15.553 128.729 15.921
202309 15.645 129.860 15.876
202312 15.442 129.419 15.723
202403 15.552 131.776 15.552

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Supernus Pharmaceuticals  (FRA:S49) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Supernus Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Supernus Pharmaceuticals (FRA:S49) Business Description

Traded in Other Exchanges
Address
9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Supernus Pharmaceuticals (FRA:S49) Headlines

No Headlines